Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by jerrycret68 and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
18 days
Number of Posts By Type
Text
17
Last Seen Tumblr Blogs
Fun Fact
When “GIF” was named word of the year in 2012, Oxford Dictionaries U.S.A. credited Tumblr for pushing the word.
Text
Creative Biolabs Presented Mechanisms Behind the Functioning of Cancer Vaccines
Creative Biolabs elaborates on the development mechanisms of DC and mRNA vaccines, two of the most promising cancer vaccine candidates.
The pursuit of competent cancer vaccines has gained unprecedented momentum in recent years, driven by groundbreaking advancements and heightened interest in immunotherapy, among which one of the most prominent results was published not a while ago—the world's first personalized mRNA cancer vaccine for melanoma, in its phase 2 trial, was proven to dramatically reduce the risk of cancer returning in patients. Lately, at a monographic report meeting, Creative Biolabs covered DC vaccines and mRNA vaccines, aiming to brief their services while asserting their determination to help global researchers in their quest to develop novel cancer treatments.
The Rising Promise of Cancer Vaccines
Cancer vaccines, designed to stimulate the immune system to recognize and attack cancer cells, represent a transformative approach to cancer treatment. The potential of these vaccines to provide long-lasting immunity and reduce relapse rates has generated substantial excitement in the scientific community. From their initial establishment, a group of scientists adept at immunology and vaccine R&D stepped into the scope and successfully established a systematic workflow for cancer vaccine discovery and validation.
"The main components of cancer vaccines are a tumor antigen, an immunological adjuvant, and a delivery carrier," according to a scientist at Creative Biolabs, "and a candidate's success depends on quite a lot of factors, involving target antigen, formulation optimization, adjuvant, and delivery systems. Each of these components must be carefully selected from miscellaneous options, thus making the process of vaccine optimization a complex problem. Creative Biolabs takes over all these assignments from you."
Two of the promising candidates were featured.
Empowering Immune Precision: DC Vaccines
Dendritic cell (DC) vaccines exploit the unique ability of dendritic cells to present antigens and activate T cells, thereby eliciting a robust immune response against cancer cells. From antigen design, dendritic cell generation, and vaccine formulation, Creative Biolabs provides a cover-all service package.
"What's more, we can construct experimental tumor models as well as assays that are in vitro to assist our customers with dendritic cell vaccine validation work," the scientist added, "in terms of safety, toxicology, ADME, and PK profiles."
Rapid Response, Lasting Impact: mRNA Vaccines
mRNA vaccines are designed to encode tumor-specific antigens, which are then translated into proteins within the body, triggering an immune response. The advent of mRNA vaccine technology offers a versatile and efficient platform for cancer vaccine development, revolutionizing the field of vaccinology. Creative Biolabs' mRNA vaccine platform provides end-to-end solutions, from mRNA synthesis to delivery system development, and covers GMP-grade mRNA manufacturing.
Building Blocks of Innovation: Premium Raw Materials for Vaccine R&D
"In addition to vaccine development services, we have off-the-shelf raw materials essential for cancer vaccine research. These materials include adjuvants, antigens, and delivery systems, all meticulously developed to meet the highest standards of quality and efficacy, with the aim of streamlining the researchers' vaccine development processes and achieving optimal results." The scientist concluded.
The briefing provides a layout of Creative Biolabs solutions and their gains after years of practical involvement in customer projects. As the field of cancer vaccine research continues to evolve, Creative Biolabs remains at the cutting edge, providing advanced solutions that drive scientific progress.
For more information, visit their website at https://www.creative-biolabs.com/vaccine/.
About Creative Biolabs is a leading biotechnology company specializing in vaccine development, antibody production, and immunotherapy solutions. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality products and services to support biomedical research and drug development worldwide.
0 notes
Text
Creative Biolabs Is Ahead of the Curve in Oncolytic Virus Therapy
Creative Biolabs significantly contributes to the advancement of oncolytic virus therapy with full-set services and blue-ribbon products.
Research is underway in labs worldwide to determine if pathogens, which are often found in humans and may cause diseases like influenza, can be utilized in a safe and effective manner to target and eliminate cancer cells, thus oncolytic viruses (OVs) emerging as the times require, which are genetically engineered viruses to infect and lyse cancer cells while sparing healthy tissue. Creative Biolabs excels in the field by offering end-to-end oncolytic virus therapy development services. In a recent release, a representative scientist highlighted their solutions for preclinical studies to ensure a comprehensive, dedicated R&D process.
Oncolytic Virus Immunogenicity Study: The Gateway to Effectiveness
"Immunogenicity is one of the most prominent problems to conquer when developing oncolytic viral drugs," according to the scientist, "which is measured by the level of anti-drug antibodies (ADAs). We can perform assays to monitor the antibodies against the oncolytic virus vector and transgene, neutralization antibodies against the oncolytic virus, and complement-mediated anti-oncolytic virus activities, thus evaluating the innate and adaptive immune response to the candidate oncolytic virus backbone and the transgene. We ensure that our clients receive comprehensive and accurate immunogenicity data."
Oncolytic Virus Efficacy Study: The Guardians of Therapeutic Viability
Preclinical in vivo efficacy studies will provide more powerful information for later development and are a critical determinant of its success for oncolytic virus therapy in clinical settings. Creative Biolabs offers robust efficacy studies with resourceful synergistic and xenograft mouse models to provide valuable insights into the virus's ability to selectively target and eliminate cancer cells, thereby supporting the development of potent and reliable cancer treatments.
"All our studies are designed to meet the highest standards of scientific rigor, which can be performed in GLP-compliant and IACUC-regulated facilities by certified technicians." The scientist said.
Oncolytic Virus Toxicology Study: The Visa for Safety
FDA guidelines require an integrated summary of the toxicologic effects of pharmaceuticals in animals and in vitro before any new drug applies for approval for listing. Creative Biolabs has developed various assays to analyze the toxicity of oncolytic viruses and the expressed transgene in terms of:
* Oncolytic virus shedding study
* Clinical observations
* Gross organ pathology
* Histopathology
* Transgene specific toxicity
* Off-target toxicity
As oncolytic virus therapy continues to gain traction as a viable cancer treatment, Creative Biolabs remains committed to driving innovation and excellence in this field. For more information about Creative Biolabs and their services, visit https://www.creative-biolabs.com/oncolytic-virus/.
About
Creative Biolabs is a leading biotechnology company dedicated to advancing biomedical research through innovative solutions. With a focus on oncolytic virus therapy, the company continues to drive advancements that redefine cancer treatment strategies globally.
0 notes
Text
Advancing Research with Ethical Precision: Creative Biolabs' NHP Biological Samples
Recent industry breakthroughs highlight the role of NHPs as a key factor in achieving more accurate preclinical results. Creative Biolabs has responded to this need by expanding its portfolio of NHP biological samples.
In the ever-evolving fields of scientific research and pharmaceutical development, non-human primates (NHPs) have emerged as critical partners. Their genetic similarity to humans makes them invaluable in preclinical studies, aiding in the understanding of human diseases and the development of new therapies. However, the use of NHPs in research is not without ethical debate, prompting the need for responsible sourcing and utilization of biological materials. Creative Biolabs, a leader in the biotechnology sector, addresses these concerns by providing high-quality NHP biological samples, including cynomolgus monkey PBMCs, NHP plasma, and endothelial cell products.
NHP PBMCs: A Gateway to Immunological Insights
"Reliable monkey PBMC sources are among the most sought-after samples for research involving immunology and drug testing," says a scientist at Creative Biolabs, "and thus we've collected Cynomolgus monkey PBMCs. These cells are indispensable for studies involving immune responses, vaccine development, and autoimmune diseases."
Creative Biolabs also provides rhesus monkey PBMCs as pivotal tools for studies ranging from infectious diseases to transplantation research, which are ensured to be ethically sourced and rigorously tested, enabling researchers to tackle global health challenges effectively.
NHP Plasma: A Decryption Key for Pharmacology
Plasma products derived from NHPs, such as those provided by Creative Biolabs, are essential for a variety of research applications, including regenerative medicine, tissue engineering, and cell culture.
"Our plasma products are collected from rigorously screened healthy donors of various monkey species, such as cynomolgus, rhesus, baboon, and cebus, and the collection process strictly adheres to animal welfare requirements. Obtained through centrifugation processing of anticoagulated whole blood, these plasma reagents do not contain blood cells or platelets to serve as primary sources for biomarkers."
Immortalized NHP Endothelial Cells: Deduce Vascular Biology
Endothelial cells play a critical role in vascular biology and related research. Creative Biolabs provides immortalized NHP endothelial cell products that function as stable and reproducible models for studying endothelial function and interaction with various therapeutic agents.
"Our immortalized NHP endothelial cells are generated by SV40 antigen T or other immortalization techniques and can be cultured continuously without any signs of senescence. These high-activity cells provide a solid foundation for establishing blood-brain barrier and blood-nerve barrier models to study vascular permeability and inflammatory responses." The scientist elaborated.
Commitment to Ethical Research and Development
Creative Biolabs is deeply committed to ethical research practices. The company's rigorous ethical standards and transparent sourcing of NHP biological samples address the growing ethical concerns within the scientific community. By partnering with Creative Biolabs, researchers can be assured of the ethical integrity and high quality of the biological materials they use.
"Our original intention to provide these NHP biological samples aims at satisfying a wide array of research needs, from basic science to advanced therapeutic development. By providing reliable, ethically sourced materials, we help researchers make significant strides in understanding diseases, developing new treatments, and improving human health." The scientist summarized.
About In a landscape where scientific advancement and ethical considerations must go hand in hand, Creative Biolabs stands out as a trusted partner for researchers worldwide. Their dedication to providing high-quality NHP biological samples, combined with a commitment to ethical practices, ensures that the vital research conducted today can lead to the medical breakthroughs of tomorrow.
0 notes
Text
One "Target" for a Month: Creative Biolabs Features TNFRSF9
Creative Biolabs introduces its range of TNFRSF9-related antibody reagents.
The growing interest in TNFRSF9 (also known as CD137, 4-1BB) stems from its role as a co-stimulatory receptor on T cells, which can enhance immune responses against tumors. Research has shown that activating TNFRSF9 can significantly boost the efficacy of cancer immunotherapies. To synchronize with recent industry news highlighting the potential of TNFRSF9-targeted therapies to overcome the limitations of existing treatments and deliver durable anti-tumor responses, Creative Biolabs specifies their anti-TNFRSF9 engineered antibodies in the monthly briefing.
I: Leading in with the Omnipresent Hi-Affi™
"First of all, a short overview of our Hi-Affi™ platform to get you a clearer picture of our antibody performance," according to the scientist delivering the presentation, "which is a concert of advanced DNA technologies and powerful cell-free expression systems."
Almost all production work of recombinant antibodies is run by the Hi-Affi™ platform, covering antibodies of different working modalities (blocking, neutralizing, etc.), antibodies against divergent targets (epitope-specific, mRNA encoded, etc.), and antibodies originated from different species (chicken, rabbit, etc.), with which the yielding reagents will be validated to have over 98% purity, high affinity, and reproducibility.
II: Catalog presentation
The scientist revealed a list of their research-use-only antibodies that are readily available for global delivery, and announced that the list is growing to cover more isotypes and more validated applications.
Rat Anti-TNFRSF9 Recombinant Antibody
Recombinant Mouse Anti-Human TNFRSF9 Antibody
Hamster Anti-TNFRSF9 Recombinant Antibody
Rat Anti-TNFRSF9 Recombinant Antibody
Rat Anti-TNFRSF9 Recombinant Antibody
Human Anti-TNFRSF9 Recombinant Antibody
Human Anti-TNFRSF9 Recombinant Antibody
III: Case study: urelumab—a therapeutic breakthrough
Furthermore, a candidate that had received its final clinical results not a while ago was discussed—urelumab, an agonistic antibody targeting 4-1BB, making it a valuable tool in the fight against cancer. Two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors were reported in the paper.
"For relevant studies, we have anti-human 4-1BB recombinant antibodies," the scientist added, "which have been validated to be positive against native human antigen. Tested data are provided on the product page to help researchers know more about how they work in specific assays, like WB and ELISA."
IV: Outlook
Creative Biolabs prides itself on its commitment to innovation and collaboration and is poised to play a pivotal role in advancing TNFRSF9-targeted therapies.
"As the research community continues to explore the full potential of such critical factors in immunotherapy, we remain dedicated to driving scientific progress." The scientist summarized.
For more information about Creative Biolabs' TNFRSF9 antibody services and to explore their comprehensive product offerings, visit https://www.creativebiolabs.net/ or contact their expert team.
Company Overview Creative Biolabs is a biotechnology company specializing in antibody development, engineering, and production. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality antibody products to support biomedical research and drug development worldwide.
0 notes
Text
Creative Biolabs: Creative Thoughts to Shake Up mRNA R&D
Creative Biolabs offers top-notch mRNA technology support to fuel emerging therapeutic discoveries.
Recent headlines have been dominated by the transformative potential of mRNA-based therapies, extending beyond infectious diseases to encompass cancer, genetic disorders, and autoimmune conditions. This surge in interest underscores the importance of reliable and innovative partners in mRNA research and development. Creative Biolabs stands out as a pivotal player, providing comprehensive solutions that streamline the drug development process and enhance the efficacy of mRNA therapeutics.
One of the key offerings of Creative Biolabs is the mRNA technology platform, which provides a kaleidoscopic toolbox for mRNA research and development. The platform integrates the lipoplyplex (LPR) technique to produce mRNA modified by specific histidylated liposomes and polymers and encoding a wide variety of tumor antigens, ensuring a streamlined development workflow, improved mRNA delivery, and reduced overall cost.
A decisive component of successful mRNA therapeutics is the delivery system. Recognizing that one size does not fit all, Creative Biolabs offers customized mRNA delivery vehicles tailored to the unique requirements of each project. Their ability to customize delivery vehicles enables researchers to optimize the therapeutic index and overcome the specific challenges associated with the candidate mRNA drugs, whether they be targeted delivery, controlled release, or enhanced cellular uptake.
"We help scheme LNP formulations to make sure that the desired therapeutic mRNA reaches its intended destination within the body, maximizing therapeutic potential while minimizing side effects. Researchers can rely on our lipid nanoparticle technology to advance their mRNA-based treatments from the laboratory to next stage trials with confidence." According to a scientist at Creative Biolabs.
Furthermore, Creative Biolabs excels in developing lipid nanoparticles, one of the prevalent options of a successful delivery system, as an essential carrier to transport mRNA therapeutics into cells with their LNP technology designed to optimize the delivery efficiency and stability of mRNA molecules, allowing for one-stop, customized LNP preparation and scalable proprietary manufacturing.
Overall, Creative Biolabs is dedicated to pushing the boundaries of mRNA technology, empowering researchers to advance their mRNA-related research projects, and playing a crucial role in driving innovation in the field of mRNA therapeutics.
To learn more about Creative Biolabs' mRNA technology services, please visit: https://mrna.creative-biolabs.com.
About In an era where precision medicine and rapid drug development are paramount, Creative Biolabs' contributions are not just relevant—they are revolutionary. Their comprehensive mRNA technology platform, coupled with pioneering lipid nanoparticle and delivery system solutions, positions them as a leader in the mRNA therapeutics arena. By partnering with Creative Biolabs, scientists and pharmaceutical companies can accelerate their research, bringing life-changing therapies to patients faster and more efficiently than ever before.
0 notes
Text
Instructions for Single-Domain Antibody Discovery
Creative Biolabs elaborates on single-domain antibody (sdAb) development and sequencing, which are designed to support scientists and pharmaceutical companies in their new drug discovery programmes.
Single domain antibodies are emerging arrows pointing at prevalent therapeutic targets and scarce ones involved in cancer, neurodegenerative disorders, and infections. Creative Biolabs introduces their sdAb discovery and profiling solutions, which contribute to harnessing the full potential of sdAbs.
"A full suite of antibody discovery, from initial discovery to advanced development stages, is provided and customised to meet each project's specifics, thus ensuring an infallible delivery." According to a scientist at Creative Biolabs.
sdAb Library Construction and Screening: Laying the Foundation
Creative Biolabs creates immunised sdAb libraries of 10–100 million clones through immunised camel, llama, alpaca, or shark and synthetic sdAb libraries by randomising the CDR1 and CDR3 using trimer codon technology. The screening process is meticulously designed to identify the most promising candidates, significantly enhancing efficiency and success rates.
Case: Anti-BBB sdAb Discovery
Breaking through the blood-brain barrier (BBB) has long been a challenge. Creative Biolabs addresses this challenge by focusing on sdAbs that can effectively penetrate the BBB, positively implying the development of biologic-based treatments for brain disorders.
"We can also target endogenous transport systems, including carrier-mediated transporters like glucose and amino acid carriers, receptor-mediated transcytosis for insulin, transferrin, or low-density lipoproteins, and active efflux transporters such as p-glycoprotein." The scientist added.
De Novo sdAb Sequencing: Search to the Bottom
The de novo sdAb sequencing is based upon the exclusive Database Assisted Shotgun Sequencing (DASS) system that Creative Biolabs manages to precisely read the sequence information of soluble and functional sdAbs with diverse origins—with 100% coverage and 100% accuracy.
"For example, mass spectrometric de novo sequencing can yield the whole camelid heavy chain antibody sequence. Leu/Ile discrepancies can be addressed by homology comparisons with known VHH sequences. Furthermore, sdAb conjugates or immobilised sdAbs are also sequenced effectively using our DASS method." The scientist commented.
For more information about Creative Biolabs and their single-domain antibody services, please visit their official website: https://www.creative-biolabs.com/.
0 notes
Text
Advancing Research with Ethical Precision: Creative Biolabs' NHP Biological Samples
Recent industry breakthroughs highlight the role of NHPs as a key factor in achieving more accurate preclinical results. Creative Biolabs has responded to this need by expanding its portfolio of NHP biological samples.
cynomolgus monkey PBMCs
In the ever-evolving fields of scientific research and pharmaceutical development, non-human primates (NHPs) have emerged as critical partners. Their genetic similarity to humans makes them invaluable in preclinical studies, aiding in the understanding of human diseases and the development of new therapies. However, the use of NHPs in research is not without ethical debate, prompting the need for responsible sourcing and utilization of biological materials. Creative Biolabs, a leader in the biotechnology sector, addresses these concerns by providing high-quality NHP biological samples, including cynomolgus monkey PBMCs, NHP plasma, and endothelial cell products.
NHP PBMCs: A Gateway to Immunological Insights
"Reliable monkey PBMC sources are among the most sought-after samples for research involving immunology and drug testing," says a scientist at Creative Biolabs, "and thus we've collected Cynomolgus monkey PBMCs. These cells are indispensable for studies involving immune responses, vaccine development, and autoimmune diseases."
Creative Biolabs also provides rhesus monkey PBMCs as pivotal tools for studies ranging from infectious diseases to transplantation research, which are ensured to be ethically sourced and rigorously tested, enabling researchers to tackle global health challenges effectively.
NHP Plasma: A Decryption Key for Pharmacology
Plasma products derived from NHPs, such as those provided by Creative Biolabs, are essential for a variety of research applications, including regenerative medicine, tissue engineering, and cell culture.
"Our plasma products are collected from rigorously screened healthy donors of various monkey species, such as cynomolgus, rhesus, baboon, and cebus, and the collection process strictly adheres to animal welfare requirements. Obtained through centrifugation processing of anticoagulated whole blood, these plasma reagents do not contain blood cells or platelets to serve as primary sources for biomarkers."
Immortalized NHP Endothelial Cells: Deduce Vascular Biology
Endothelial cells play a critical role in vascular biology and related research. Creative Biolabs provides immortalized NHP endothelial cell products that function as stable and reproducible models for studying endothelial function and interaction with various therapeutic agents.
"Our immortalized NHP endothelial cells are generated by SV40 antigen T or other immortalization techniques and can be cultured continuously without any signs of senescence. These high-activity cells provide a solid foundation for establishing blood-brain barrier and blood-nerve barrier models to study vascular permeability and inflammatory responses." The scientist elaborated.
Commitment to Ethical Research and Development
Creative Biolabs is deeply committed to ethical research practices. The company's rigorous ethical standards and transparent sourcing of NHP biological samples address the growing ethical concerns within the scientific community. By partnering with Creative Biolabs, researchers can be assured of the ethical integrity and high quality of the biological materials they use.
"Our original intention to provide these NHP biological samples aims at satisfying a wide array of research needs, from basic science to advanced therapeutic development. By providing reliable, ethically sourced materials, we help researchers make significant strides in understanding diseases, developing new treatments, and improving human health." The scientist summarized.
About In a landscape where scientific advancement and ethical considerations must go hand in hand, Creative Biolabs stands out as a trusted partner for researchers worldwide. Their dedication to providing high-quality NHP biological samples, combined with a commitment to ethical practices, ensures that the vital research conducted today can lead to the medical breakthroughs of tomorrow.
0 notes
Text
Applications of Oncolytic Viruses in Cancer Treatment
0 notes
Text
Introduction and Mechanism of Oncolytic Virus Therapy
0 notes
Text
Bacterial Artificial Chromosome (BAC) Technology
0 notes